Page last updated: 2024-12-11
finrozole
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
finrozole: an aromatase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6918277 |
| SCHEMBL ID | 2138489 |
| MeSH ID | M0288512 |
Synonyms (14)
| Synonym |
|---|
| finrozole |
| mpv-2213ad |
| 4-[(1r,2s)-3-(4-fluorophenyl)-2-hydroxy-1-(1,2,4-triazol-1-yl)propyl]benzonitrile |
| finrozole [inn] |
| 160146-17-8 |
| unii-40028khq6b |
| p-((1rs,2sr)-3-(p-fluorophenyl)-2-hydroxy-1-(1h-1,2,4-triazol-1-yl)propyl)benzonitrile |
| benzonitrile, 4-(3-(4-fluorophenyl)-2-hydroxy-1-(1h-1,2,4-triazol-1- yl)propyl)-, (r*,s*)-(+-)- |
| 40028khq6b , |
| SCHEMBL2138489 |
| benzonitrile, 4-((1r,2s)-3-(4-fluorophenyl)-2-hydroxy-1-(1h-1,2,4-triazol-1-yl)propyl)-, rel- |
| DTXSID90166806 |
| Q15633964 |
| AKOS040748353 |
Research Excerpts
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Treatment with finrozole, a specific aromatase inhibitor, caused an involution of the differentiated phenotype of the mammary gland, marked by the disappearance of alveolar structures and the majority of the tertiary side branches of the ducts." | ( Mammary gland development in transgenic male mice expressing human P450 aromatase. Ahonen, T; Li, X; Mäkelä, S; Poutanen, M; Santti, R; Streng, T; Wärri, A, 2002) | 0.65 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " The Cmax values increased as the dose increased." | ( Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men. Ahokoski, O; Halonen, K; Huupponen, R; Irjala, K; Kangas, L; Manninen, P; Salminen, E; Scheinin, H; Taalikka, M, 2001) | 0.63 |
| "The absorption of finrozole from the tablet formulation was relatively rapid, and the apparent elimination half-life was longer after the tablet than after the solution, probably reflecting overlap of the absorption with the elimination phase." | ( Pharmacokinetics of finrozole (MPV-2213ad), a novel selective aromatase inhibitor, in healthy men. Ahokoski, O; Halonen, K; Huupponen, R; Irjala, K; Kangas, L; Manninen, P; Salminen, E; Scheinin, H; Taalikka, M, 2001) | 0.97 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (12)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 20.90
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.90) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (38.46%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (61.54%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||